Abstract:Objective To examine the relative impact of three management options in patients aged <60 years with cryptogenic stroke and a patent foramen ovale (PFO): PFO closure plus antiplatelet therapy, antiplatelet therapy alone and anticoagulation alone. Design Systematic review and network meta-analysis (NMA) supported by complementary external evidence. Data sources Medline, EMBASE and Cochrane CENTRAL. Study selection Randomised controlled trials (RCTs) addressing PFO closure and/or medical therapies in patients with PFO and cryptogenic stroke. Review methods We conducted an NMA complemented with external evidence and rated certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Results Ten RCTs in eight studies proved eligible (n=4416). Seven RCTs (n=3913) addressed PFO closure versus medical therapy. Of these, three (n=1257) addressed PFO closure versus antiplatelet therapy, three (n=2303) addressed PFO closure versus mixed antiplatelet and anticoagulation therapies and one (n=353) addressed PFO closure versus anticoagulation. The remaining three RCTs (n=503) addressed anticoagulant versus antiplatelet therapy. PFO closure versus antiplatelet therapy probably results in substantial reduction in ischaemic stroke recurrence (risk difference per 1000 patients over 5 years (RD): -87, 95% credible interval (CrI) -100 to -33; moderate certainty). Compared with anticoagulation, PFO closure may confer little or no difference in ischaemic stroke recurrence (low certainty) but probably has a lower risk of major bleeding (RD -20, 95% CrI -27 to -2, moderate certainty). Relative to either medical therapy, PFO closure probably increases the risk of persistent atrial fibrillation (RD 18, 95% CI +5 to +56, moderate certainty) and device-related adverse events (RD +36, 95%CI +23 to +50, high certainty). Anticoagulation, compared with antiplatelet therapy, may reduce the risk of ischaemic stroke recurrence (RD -71, 95% CrI -100 to +17, low certainty), but probably increases the risk of major bleeding (RD +12, 95% CrI -5 to +65, moderate certainty). Conclusions In patients aged <60 years, PFO closure probably confers an important reduction in ischaemic stroke recurrence compared with antiplatelet therapy alone but may make no difference compared with anticoagulation. PFO closure incurs a risk of persistent atrial fibrillation and device-related adverse events. Compared with alternatives, anticoagulation probably increases major bleeding.

Risk of Ischemic Stroke After Patent Foramen Ovale Closure

Recurrent Ischemic Stroke/Transient Ischemic Attack After Patent Foramen Ovale Closure: A cohort study

Comparison of Stroke Recurrence Between Antiplatelet and Closure Therapy in Cryptogenic Stroke Patients with Patent Foramen Ovale and Its Influencing Factors

Patent Foramen Ovale Closure for Patients with Cryptogenic Stroke: A Systematic Review and Comprehensive Meta‐analysis of 5 Randomized Controlled Trials and 14 Observational Studies

Safety and Long-Term Results of Patent Foramen Ovale Transcatheter Closure in Patients with Thrombophilia.

Propensity-score matched analysis of patent foramen ovale closure in real-world study cohort with cryptogenic ischemic stroke

Patent foramen ovale closure versus drug therapy in patients over 60 years and a follow‐up of 5 years

Insights from a 23-Year Monocentric Analysis

The Incidence of Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure Detected by Implantable Loop Recorders

Abstract TP249: A Real World Study of PFO Closure in Young Patients With Ischemic Stroke

Percutaneous Closure Versus Medical Therapy for Stroke with Patent Foramen Ovale: a Systematic Review and Meta-Analysis

Device Closure or Antithrombotic Therapy After Cryptogenic Stroke in Elderly Patients With a High-Risk Patent Foramen Ovale

Determinants of adverse outcomes following patent foramen ovale closure in elderly patients

Long-Term Outcomes and Complications of Intracardiac Echocardiography-Assisted Patent Foramen Ovale Closure in 1,000 Consecutive Patients.

Residual Shunt after Patent Foramen Ovale Closure: Preliminary Results from Italian Patent Foramen Ovale Survey

Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation in Patients with Patent Foramen Ovale and Cryptogenic Stroke: a Systematic Review and Network Meta-Analysis Incorporating Complementary External Evidence

Patent Foramen Ovale Closure for Nonstroke Indications

[Patent foramen ovale and stroke]

Patent Foramen Ovale with Paradoxical Embolism: Mid‐Term Results of Transcatheter Closure in 256 Patients

Percutaneous Patent Foramen Ovale Closure in Patients with Cryptogenic Stroke or Transient Ischemic Attack: A Retrospective Study.

Cost effectiveness of percutaneous closure versus medical therapy for cryptogenic stroke in patients with a patent foramen ovale